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For Whom?Spencer B. King III, MD, MACC, Editor-in-Chief, JACC: Cardiovascular InterventionsI hate the term “risk avoidance.” Why? It is notbecause I don’t want to reduce risk for patients.Risk and risk reduction are critical components
in all our clinical trials and observational studies.
We think about it in all our clinical decisions. How
do I reduce the risk for my patient? If we could avoid
risk for her, wouldn’t it be even better? These are no-
ble thoughts when applied to the patient, but now
risk avoidance has become a dirty word (2 words)
when applied to the doctor or hospital. Conversations
in doctors’ lounges across the country are about
nonmedical issues, mostly sports or politics, or med-
ical issues. The medical ones that are most con-
structive are about difﬁcult cases and informal
consultation (of course, with HIPAA [the Health In-
surance Portability and Accountability Act] in mind),
or depressing ones about electronic medical records,
outcome reporting, and reimbursement issues. In
cardiology, when we are discussing patient risk and
selection of therapy to reduce that risk, the conversa-
tions are upbeat. However, the risk being increasingly
talked about is the physicians’ risk. For me that is
depressing. Opinion pieces sent to JACC: Cardiovas-
cular Interventions, as well as physician complaints
about public reporting and the use of outcome mea-
sures tied to reimbursement, are increasingly domi-
nating the pessimistic conversations.
Let’s think about 2 ends of the spectrum. On the one
hand are outcomemeasures, usually death, which is of
great interest to the physician and the patient. After
all, we are here to save lives or to decrease the risk of
dying. But risk avoidance is now used to describe a
method of improving scorecards by avoiding treat-
ment for patients who are at high risk of dying.
Extensive efforts at risk adjustment have not
convinced many physicians that taking on high-riskpatients does not put their scorecard in jeopardy. I
have learned that risk adjustment is much more
favorable to those who treat high-risk patients, but it is
not perfect. I ﬁnd it hard to believe that there are many
physicians who withhold therapy they think will be
beneﬁcial because of the chance that the outcome may
not be favorable. There are, however, very high-risk
situations, such as patients who present after cardiac
arrest with anoxic encephalopathy or patients who are
in refractory shock and perhaps other scenarios in
which the physician views the intervention to have a
questionable chance of altering the outcome. Among
surgeons, this has always been part of the discussion.
“I don’t think the patient will make it through surgery”
is the powerful balancing concept. For those per-
forming coronary interventions, the risk of the pro-
cedure is less, the time to decide is less, and therefore
the decision to intervene or not in these cases is
sometimes more difﬁcult. Nonetheless, it is a decision
that should be made in consultation with the family
and should not be driven by concern about score-
carding of the outcome. Whether outcomes reporting
is to the public or to payers or regulators, these
“compassionate cases” are few enough to make sta-
tistical adjustment of risk for physicians difﬁcult. This
is why these cases were removed from public report-
ing in New York State after 2008. However, there is a
necessity to generate a clear deﬁnition of the
“compassionate case” patient and a reliable way to
ensure that it is adhered to. If some cases are to be
excluded from reporting on a national level in
response to the concern about risk avoidance, a broad
consensus about the deﬁnition of such cases will be
required. Discussions are ongoing at the Interven-
tional Council and the Board of Governors of the
American College of Cardiology.
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111On the other end of the provider risk avoidance
spectrum is scorecarding for the appropriateness of
therapy, and now the meaningful use of therapy.
These concepts imply that there are therapies that can
be done but should not be done because of lack of
demonstrated superiorities or because their “value” in
monetary terms is not worth the outcome achieved.
Whereas the risk avoidance of high-risk patients
leading to excess mortality is viewed as a restriction in
the access to care, the intervention in cases not
considered as appropriate is viewed as overuse of
therapies. The appropriate use criteria continue to
evolve but are not yet perfect. It is designed as a
quality improvement tool but has now become
another driver of risk avoidance, the risk of ﬁnancial
penalty. Concern has been expressed that cases not
labeled “appropriate” may have reimbursement
denied by payers. Whether this comes to be or not, the
concern is there and has led some practices to
upcoding so that the number of patients not having
the appropriate designations continues to decrease.
There is no doubt that rules will inﬂuence behavior.
Some will be constructive changes—that is what
quality initiatives are supposed to be about. But some
changes will be cosmetic with the reporting adjusted
to ﬁt the rules. Do these risk avoidance measures have
to continue to dominate decision making? Can we re-
turn to the primary question—how to reduce the risk
for the patient? Transparency is demanded and the
days of turning a blind eye to the selection of therapiesor the outcomes achieved are over. We will always
have record keeping, and it will be necessary if true
quality is to be maintained and improved. Most phy-
sicians would support reporting if all data is consid-
ered and the playing ﬁeld is level. The incentives,
however, need to be reordered. If reimbursement is to
be tied to outcome and to correct selection of therapy,
the methods of assessing these must be adequate.
Administrative databases do not contain the infor-
mation necessary to perform risk adjustment. They
should not be used for determining rewards or pen-
alties for physicians or hospitals. Adequately adjusted
clinical data is necessary. As long as fee-for-service
dominates health care ﬁnancing, the incentives will
drive increased utilization. To understand whether it
is appropriate, we need to know more than who
receives the therapy and their outcomes; we also need
to know who does not get therapy and their outcomes.
Administrative databases are accumulating large
amounts of data, but, remember, they are not able to
reﬂect proper risk adjustment. We will need much
more comprehensive clinical data and perhaps a
change in the incentives. I often wonder, do our col-
leagues in Canada or Europe have their conversations
in the doctors’ lounge dominated by “risk avoidance”?
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